Drugs / lurtotecan
lurtotecan
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00006036 | Mar 2000 → Sep 2002 | head and neck cancer, lung cancer, ovarian cancer | NCIC Clinical Trials Group | Completed | No outcome recorded |
| Phase 1 | NCT00003891 | Feb 1999 → Jun 2001 | cancer of unknown primary site | NCIC Clinical Trials Group | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00022594 | May 2001 → Aug 2002 | head and neck cancer | European Organisation for Research and Treatment of Cancer - EORTC | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | lurtotecan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00003891 ↗ |
| Known as | GI-147211C | ChEMBL registry synonym — accepted as the source's own label CHEMBL305666 ↗ |
| Known as | LURTOTECAN DIHYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL305666 ↗ |
| Known as | NX211 | “PURPOSE: To define the maximum tolerated dose (MTD), recommended phase II dose (RD) and dose limiting toxicity (DLT) of liposomal lurtotecan, OSI-211 (formerly known as NX211),...” PMID 15122073 ↗ Aug 20041“OSI-211 (also known as NX211) is a liposomal preparation of the topoisomerase I inhibitor, lurtotecan, which has shown antitumor activity in phase I and II clinical trials.” PMID 15033677 ↗ Apr 2004 |
| Known as | OSI-211 | “The purpose of this study was to evaluate the activity and safety of OSI-211, the liposomal form of lurtotecan, in patients ineligible for curative surgery or radiotherapy and...” PMID 15571957 ↗ Dec 20042“PURPOSE: To define the maximum tolerated dose (MTD), recommended phase II dose (RD) and dose limiting toxicity (DLT) of liposomal lurtotecan, OSI-211 (formerly known as NX211),...” PMID 15122073 ↗ Aug 2004 “OSI-211 (also known as NX211) is a liposomal preparation of the topoisomerase I inhibitor, lurtotecan, which has shown antitumor activity in phase I and II clinical trials.” PMID 15033677 ↗ Apr 2004 |
| Action | Inhibit | “the topoisomerase I inhibitor, lurtotecan” PMID 15033677 ↗ Apr 2004 |
| Modality | Small molecule | — CHEMBL305666 ↗ |
| Route | Intravenous | “given as a short intravenous infusion” PMID 15122073 ↗ Aug 2004 |